
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings is a commercial-stage biotechnology company with a deep pipeline in multiple therapeutic areas. Its lead product, KIMMTRAK, has demonstrated strong sales growth and market penetration, and its Phase 3 trial data has shown significant overall survival benefit in treating HLA-A*02:01-positive metastatic uveal melanoma (mUM). The company also has a robust pipeline with multiple drug candidates targeting various oncology, infectious, and autoimmune diseases, with upcoming late-stage readouts that could further strengthen its position in the biotech industry. The company's strong financials and potential for future growth make it a promising investment opportunity.
Bears say
Immunocore Holdings is a commercial-stage biotechnology company with a pipeline of drug candidates targeting multiple therapeutic areas including oncology, infectious disease, and autoimmune disease. While their lead product KIMMTRAK has shown success in treating uveal melanoma, the company's reliance on this small patient pool could lead to increased rebates and discounts on a potential label expansion. Additionally, the regulatory landscape for TCR-based therapies is still relatively unknown, which could impact the development and approval of Immunocore's drugs in the future. Overall, these factors contribute to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares